CYTK
CYTOKINETICS INC
Latest Form 4:Sale$702KbyCallos Andrew (EVP, Chief Commercial Officer) · filed Aug 31, 2026
CYTOKINETICS INC (CYTK) has 128 SEC Form 4 filings (208 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 31, 2026.
The most active filer is EVP, Chief Commercial Officer Callos Andrew with 22 filings. Insiders have net sold $30.6M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Robert I. Blum
- Employees:498
- HQ:South San Francisco, CA, US
- IPO:2004-04-30
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$45.1M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$9.9B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| EVP, Chief Commercial Officer | Sale | 10,000 | $702K | Aug 31 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $527K | Aug 31 | SEC ↗ | |
| EVP Research & Development | Sale | 3,500 | $265K | Aug 18 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $576K | Aug 10 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 14,000 | $1.1M | Jul 30 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $607K | Jul 27 | SEC ↗ | |
| EVP Research & Development | Sale | 3,500 | $282K | Jul 23 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $615K | Jul 14 | SEC ↗ | |
| EVP Research & Development | Sale | 3,500 | $303K | Jul 7 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 15,000 | $1.3M | Jul 2 | SEC ↗ | |
| EVP, Chief Financial Officer | Sale | 1,112 | $98K | Jul 2 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $637K | Jul 2 | SEC ↗ | |
| EVP, Chief Financial Officer | Sale | 38,730 | $3.2M | Jun 29 | SEC ↗ | |
| EVP, Chief Financial Officer | Sale | 3,134 | $266K | Jun 29 | SEC ↗ | |
| EVP Research & Development | Sale | 3,500 | $278K | Jun 23 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $528K | Jun 15 | SEC ↗ | |
| EVP Research & Development | Sale | 3,500 | $238K | Jun 9 | SEC ↗ | |
Kaye Edward M. MDFirst in 6 months | Director | Sale | 2,933 | $223K | Jun 1 | SEC ↗ |
| EVP, Chief Commercial Officer | Sale | 15,000 | $1.1M | Jun 1 | SEC ↗ | |
| Director | Sale | 5,000 | $370K | Jun 1 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $579K | May 28 | SEC ↗ | |
| EVP Research & Development | Sale | 3,500 | $265K | May 20 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $584K | May 14 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 11,333 | $875K | May 5 | SEC ↗ | |
| EVP Research & Development | Sale | 3,500 | $271K | May 5 | SEC ↗ | |
WIERENGA WENDELLFirst in 4 months | Director | Sale | 4,032 | $302K | May 5 | SEC ↗ |
HENDERSON JOHN TFirst in 5 months | Director | Sale | 20,000 | $1.5M | May 5 | SEC ↗ |
| EVP, Chief Financial Officer | Sale | 23,906 | $1.8M | May 5 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 15,857 | $1.0M | May 4 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 15,000 | $949K | Apr 30 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $447K | Apr 29 | SEC ↗ | |
| EVP Research & Development | Sale | 3,500 | $230K | Apr 21 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 7,449 | $492K | Apr 15 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $490K | Apr 15 | SEC ↗ | |
| EVP Research & Development | Sale | 4,500 | $293K | Apr 8 | SEC ↗ | |
| President & CEO | Sale | 7,500 | $500K | Apr 1 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 3,639 | $237K | Mar 31 | SEC ↗ | |
| President & CEO | Sale | 36,601 | $2.3M | Mar 18 | SEC ↗ | |
| EVP Research & Development | Sale | 12,033 | $748K | Mar 18 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 8,542 | $531K | Mar 18 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 1,930 | $120K | Mar 18 | SEC ↗ | |
Lee SungFirst filing | EVP, Chief Financial Officer | Sale | 4,935 | $307K | Mar 18 | SEC ↗ |
| EVP, Chief Commercial Officer | Sale | 1,709 | $104K | Mar 16 | SEC ↗ | |
| EVP Research & Development | Sale | 2,907 | $177K | Mar 10 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 2,582 | $157K | Mar 10 | SEC ↗ | |
Blum Robert IFirst in 4 months | President & CEO | Sale | 7,931 | $482K | Mar 10 | SEC ↗ |
| EVP, Chief Commercial Officer | Sale | 26,000 | $1.6M | Mar 5 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 886 | $55K | Mar 2 | SEC ↗ | |
| Director | Sale | 5,000 | $306K | Mar 2 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 15,000 | $929K | Feb 5 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 886 | $55K | Feb 2 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 15,000 | $904K | Jan 5 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 1,798 | $113K | Jan 2 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 1,809 | $113K | Dec 30 | SEC ↗ | |
| Director | Sale | 20,000 | $1.3M | Dec 23 | SEC ↗ | |
| EVP Research & Development | Sale | 2,200 | $135K | Dec 16 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 1,042 | $69K | Dec 8 | SEC ↗ | |
Callos AndrewFirst filing | EVP, Chief Commercial Officer | Sale | 52,486 | $3.5M | Dec 5 | SEC ↗ |
| Director | Sale | 28,064 | $1.9M | Dec 2 | SEC ↗ | |
| EVP Research & Development | Sale | 2,200 | $141K | Dec 2 | SEC ↗ | |
HENDERSON JOHN TFirst filing | Director | Sale | 8,750 | $559K | Dec 2 | SEC ↗ |
Harrington Robert ArthurFirst in 3 months | Director | Sale | 2,150 | $144K | Dec 2 | SEC ↗ |
| Director | Sale | 5,000 | $324K | Nov 19 | SEC ↗ | |
| EVP Research & Development | Sale | 2,200 | $146K | Nov 18 | SEC ↗ | |
| Director | Sale | 5,175 | $337K | Nov 12 | SEC ↗ | |
| EVP Research & Development | Sale | 2,295 | $137K | Nov 4 | SEC ↗ | |
| President & CEO | Sale | 5,000 | $314K | Oct 30 | SEC ↗ | |
WIERENGA WENDELLFirst filing | Director | Sale | 4,375 | $257K | Oct 27 | SEC ↗ |
| EVP Research & Development | Sale | 2,105 | $123K | Oct 21 | SEC ↗ | |
| President & CEO | Sale | 5,000 | $300K | Oct 16 | SEC ↗ | |
| EVP Research & Development | Sale | 2,000 | $121K | Oct 7 | SEC ↗ | |
| Director | Sale | 6,757 | $405K | Oct 6 | SEC ↗ | |
| President & CEO | Sale | 5,000 | $275K | Oct 1 | SEC ↗ | |
| Director | Sale | 6,695 | $369K | Sep 30 | SEC ↗ | |
| EVP Research & Development | Sale | 2,000 | $99K | Sep 23 | SEC ↗ | |
| President & CEO | Sale | 5,000 | $249K | Sep 15 | SEC ↗ | |
Malik Fady IbrahamFirst filing | EVP Research & Development | Sale | 2,000 | $103K | Sep 10 | SEC ↗ |
Blum Robert IFirst filing | President & CEO | Sale | 5,000 | $244K | Sep 2 | SEC ↗ |
Kaye Edward M. MDFirst filing | Director | Sale | 6,756 | $338K | Sep 2 | SEC ↗ |
Harrington Robert ArthurFirst filing | Director | Sale | 2,150 | $105K | Sep 2 | SEC ↗ |
Congress trading CYTK
See timeline →- DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-06-30
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
CYTOKINETICS INC is in the Healthcare sector.